This study investigated the role of kinins and their receptors in malignant brain tumors. As a first approach, GL-261 glioma cells were injected (2 × 10 cells in 2 μl/2 min) into the right striatum of adult C57/BL6 wild-type, kinin B and B receptor knockout (KOBR and KOBR) and B and B receptor double knockout mice (KOBBR). The animals received the selective BR (SSR240612) and/or BR (HOE-140) antagonists by intracerebroventricular (i.c.v.) route at 5, 10, and 15 days. The tumor size quantification, mitotic index, western blot analysis, quantitative autoradiography, immunofluorescence, and confocal microscopy were carried out in brain tumor samples, 20 days after tumor induction. Our results revealed an uncontrolled tumor growing in KOBR or SSR240612-treated mice, which was blunted by BR blockade with HOE-140, suggesting a crosstalk between BR and BR in tumor growing. Combined treatment with BR and BR antagonists normalized the upregulation of tumor BR and decreased the tumor size and the mitotic index, as was seen in double KOBBR. The BR was detected on astrocytes in the tumor, indicating a close relationship between this receptor and astroglial cells. Noteworthy, an immunohistochemistry analysis of tumor samples from 16 patients with glioma diagnosis revealed a marked BR immunopositivity in low-grade gliomas or in older glioblastoma individuals. Furthermore, the clinical data revealed a significantly higher immunopositivity for BR, when compared to a lower BR immunolabeling. Taken together, our results show that blocking simultaneously both kinin receptors or alternatively stimulating BR may be of therapeutic value in the treatment of brain glioblastoma growth and malignancy.